Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296 | 0.79 | DPYD (0.59) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL14177211 | 0.79 | DPYD (0.59) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL403502 | 0.77 | DPYD (0.52) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL887830 | 0.75 | DPYD (0.58) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL1557319 | 0.75 | DPYD (0.53) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL3485393 | 0.75 | DPYD (0.53) | DPYDALDH1A1MAPTGAAATAD2 | |
| Eniluracil SCHEMBL37817 | 0.74 | DPYD (1.00) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL189451 | 0.74 | DPYD (1.00) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL1890981 | 0.72 | DPYD (0.50) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL6510854 | 0.71 | DPYD (0.49) | DPYDALDH1A1MAPTGAAATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184232-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | SPECTOR THOMAS (US) | 2013-07-18 | — | — | US | claimed |
| US-8440442-B2 | Method of assaying 5-FU | MYRIAD GENETICS, INC (US) | 2013-05-14 | — | — | US | claimed |
| EP-2488182-A1 | TREATING NEUROTOXICITY ASSOCIATED WITH COMBINATIONS OF 5 - FU OR ITS PRODRUGS AND DPD INHIBITORS | Adherex Technologies, Inc. (CA) | 2012-08-22 | — | — | EP | claimed |
| US-20110130359-A1 | METHODS FOR PREVENTING OR REDUCING NEUROTOXICITY ASSOCIATED WITH ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES, INC. (US) | 2011-06-02 | — | — | US | claimed |
| WO-2011047195-A1 | TREATING NEUROTOXICITY ASSOCIATED WITH COMBINATIONS OF 5 - FU OR ITS PRODRUGS AND DPD INHIBITORS | ADHEREX TECHNOLOGIES, INC. (CA) | 2011-04-21 | — | — | WO | claimed |
| WO-2009100367-A2 | COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME | ADHEREX TECHNOLOGIES INC. (CA) | 2009-08-13 | — | — | WO | claimed |
| US-20090196833-A1 | COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME | ADHEREX TECHNOLOGIES INC. (CA) | 2009-08-06 | — | — | US | claimed |
| US-20080255168-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-10-16 | — | — | US | claimed |
| EP-1827443-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | Adherex Technologies, Inc. (CA) | 2007-09-05 | — | — | EP | claimed |
| WO-2006060697-A9 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES INC (CA) | 2006-09-21 | — | — | WO | claimed |
| US-20060148753-A1 | Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs | ADHEREX TECHNOLOGIES, INC. (CA) | 2006-07-06 | — | — | US | claimed |
| WO-2006060697-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES, INC. (CA) | 2006-06-08 | — | — | WO | claimed |
| EP-0985415-A1 | Uracil reductase inactivators | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-03-15 | — | — | EP | claimed |
| US-5817664-A | ANTITUMOR, ANTICANCER AGENTS | GLAXO WELLCOME INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-3792634-A2 | METHOD OF ASSAYING 5-FU | Myriad Genetics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-2488182-B1 | Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors | ELION ONCOLOGY LLC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-0539442-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992004901-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992001452-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | disclosed |